ReviewBMC women's health2025
Recurrent bilateral giant breast fibroadenomas with a somatic PIK3CA p.G106V mutation: case report and review of current evidence.
Review in BMC women's health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundFibroadenomas are common benign breast tumors, but recurrent bilateral giant fibroadenomas are rare. Recent studies suggest genetic factors, such as PIK3CA mutations, may influence tumor behavior. CASE PRESENTATION: A 23-year-old woman with prior multiple fibroadenoma excisions presented with progressively enlarging bilateral breast masses and marked deformity. Imaging revealed multiple well-circumscribed lesions, the largest measuring 7.5 cm. Serum prolactin was elevated; estradiol and progesterone were normal. She underwent bilateral excision with reduction mammoplasty and nipple–areolar reconstruction. Histology confirmed fibroadenomas with epithelial hyperplasia; immunohistochemistry showed diffuse estrogen receptor positivity (>90% of cells) and a Ki-67 index of 5–10%. Next-generation sequencing detected a somatic PIK3CAc.317G>T (p.G106V) mutation.
conclusionIntegration of histological, hormonal, and molecular findings can guide individualized management of recurrent fibroadenomas. Large-scale studies are required to assess the prognostic significance of PIK3CA mutations in benign breast tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.